Arizona is currently home to 1662 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
NCT04023331
Recruiting
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Gender:
ALL
Ages:
All
Trial Updated:
07/05/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Register for Updates
Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)
NCT04893837
Recruiting
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
07/03/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Brain Injuries, Traumatic
Register for Updates
Pediatric Prehospital Airway Resuscitation Trial
NCT06364280
Recruiting
This study is a Phase 3, multi-center, Bayesian Adaptive Sequential Platform Trial testing the effectiveness of different prehospital airway management strategies in the care of critically ill children. Emergency Medical Services (EMS) agencies affiliated with the Pediatric Emergency Care Applied Research Network (PECARN) will participate in the trial. The study interventions are strategies of prehospital airway management: \[BVM-only\], \[BVM followed by SGA\] and \[BVM followed by ETI\]. The p... Read More
Gender:
ALL
Ages:
Between 24 hours and 17 years
Trial Updated:
07/02/2024
Locations: University of Airzona, Tucson, Arizona
Conditions: Heart Arrest, Out-Of-Hospital, Wounds and Injuries, Respiratory Insufficiency in Children, Child, Only, Critical Illness
Register for Updates
Improving Outcomes in PICS With Home-Based Program of Rehabilitation and Health Coaching
NCT06184308
Recruiting
The purpose of this study is to gather information on the effectiveness of a home-based rehabilitation program that also includes health coaching in patients who may suffer from post-intensive care syndrome (PICS). Many patients who are admitted to a hospital ICU suffer from new or worsening symptoms related to their medical condition and ICU care. These new or worsening symptoms may persist for some time and are collectively called post-intensive care syndrome (PICS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Post-Intensive Care Syndrome
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS)
NCT05895552
Recruiting
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of RTA 901 in qualified participants with Diabetic Peripheral Neuropathic Pain (DPNP). Each study part will be randomized into 3 treatment arms; 2 different doses of RTA 901 and RTA 901-maching placebo. The doses of RTA 901 in Part 2 will be selected based on the Exposure-Response (E-R) analyses of data from Part 1. A total of 384 participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Centricity Research Phoenix Multispecialty, Mesa, Arizona
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury
NCT06282965
Recruiting
The goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI). The main questions this trial aims to answer are: * Is Angiotensin (1-7) safe? * Does Angiotensin (1-7) improve mental functioning and reduce physical signs of brain damage in people who have suffered a moderate to severe TBI? Participants will: * Complete 21 days of study treatment co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Traumatic Brain Injury
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Arizona Oncology Associates, PC, Phoenix, Arizona
Conditions: Breast Cancer
Register for Updates
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
NCT04514653
Recruiting
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for tre... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
06/25/2024
Locations: Phoenix Location, Phoenix, Arizona
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Register for Updates
Pharmacogenomics of Warfarin in Hispanics and Latinos
NCT02972385
Recruiting
Warfarin is a commonly used blood thinner to treat and prevent blood clots. It is important to take the right dose of warfarin because too much can increase the risk of bleeding and too little can increase the risk of blood clots. This is why patients are closely monitored especially when they begin warfarin therapy. When clinicians prescribe warfarin, they have to consider different factors such as patient's age, body size, diet, and other medications that can interact with warfarin. Certain g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona
Conditions: Thrombosis, Hemorrhage
Register for Updates
Pharmacogenomics of Heparin-Induced Thrombocytopenia
NCT02717039
Recruiting
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Banner University Medical Center - Tucson, Tucson, Arizona
Conditions: Heparin-induced Thrombocytopenia
Register for Updates